What it isNucleotide analog inhibiting HBV polymerase; chronic hepatitis B.
Why this oneIt retains activity against lamivudine-resistant virus.
What limits itDose-dependent nephrotoxicity and a low resistance barrier mean tenofovir and entecavir have replaced it. Hepatitis can flare on stopping.
BOXED WARNING Severe acute hepatitis exacerbations after discontinuation; nephrotoxicity with chronic use in at-risk patients; HIV resistance if unrecognized/untreated HIV; lactic acidosis and severe hepatomegaly with steatosis (nucleoside analogs).
FDA dosing
Population
Start
Target
Max
Chronic hepatitis B (adequate renal function)
Adults
10 mg QD
10 mg QD (optimal duration unknown)
10 mg QD
Chronic hepatitis B (adequate renal function)
Peds >=12 yr (not recommended <12 yr)
10 mg QD
10 mg QD
10 mg QD
Renal Adults: CrCl >=50: 10 mg q24h; 30-49: 10 mg q48h; 10-29: 10 mg q72h; hemodialysis: 10 mg q7d following dialysis. No recommendation for non-HD CrCl <10 or for adolescents with renal impairment
Hepatic No adjustment needed (label: no change in dosing required in hepatic impairment)
Instructions
Oral, with or without food
Offer HIV antibody testing before initiating
Monitor hepatic function closely for at least several months after discontinuation
Monitor renal function during treatment, esp. in at-risk patients
Cautions
Severe acute hepatitis exacerbation on discontinuation — monitor hepatic function after stopping
Nephrotoxicity (delayed, gradual creatinine rise) with chronic use — monitor renal function; adjust dosing interval
HIV resistance may emerge in unrecognized/untreated HIV — test before starting
Lactic acidosis / severe hepatomegaly with steatosis, incl. fatal cases
Do not use concurrently with tenofovir disoproxil fumarate or tenofovir alafenamide products
Clinical resistance: use with lamivudine in lamivudine-resistant HBV; consider modifying treatment if HBV DNA remains >1000 copies/mL